PMID- 36531713
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221222
IS  - 2297-055X (Print)
IS  - 2297-055X (Electronic)
IS  - 2297-055X (Linking)
VI  - 9
DP  - 2022
TI  - Safety, efficacy, and clinical outcomes of transcatheter tricuspid valve 
      replacement: One-year follow-up.
PG  - 1019813
LID - 10.3389/fcvm.2022.1019813 [doi]
LID - 1019813
AB  - OBJECTIVE: The aim was to evaluate the safety and efficacy of TTVR in patients 
      with severe TR at the 1-year follow-up. MATERIALS AND METHODS: This project was a 
      single-center, observational study. From September 2020 to May 2021, 15 patients 
      with severe or extremely severe TR at high risk of traditional surgery were 
      enrolled. All patients had preoperative imaging assessments to evaluate the 
      tricuspid valve and the anatomy of the right heart. All patients were planned to 
      treated with the LuX-Valve (Ningbo Jenscare Biotechnology, Ningbo, China). The 
      LuX-Valve was implanted under the intraoperative guidance of TEE and X-ray 
      fluoroscopy. Data were collected at baseline, before discharge, and at 30 days, 6 
      months, and 1 year postoperatively. RESULTS: The LuX-Valves were successfully 
      implanted in all 15 patients. TR was significantly reduced to </= 2 +. One patient 
      died on postoperative day 12 of a pulmonary infection that was considered 
      unrelated to the procedures or the devices. The remaining 14 patients (100.0%) 
      reached the primary end point. One patient (7.1%) was rehospitalized during 
      1-year follow-up because of device thrombosis. The number of patients who 
      survived at 1 year with New York Heart Association (NYHA) functional class II was 
      higher than that before TTVR (11/14 vs. 0/15, P = 9.11 x 10(-4)). Patients with 
      peripheral edema and ascites decreased from 100.0 to 46.7% at baseline to 28.6% 
      and 14.3% at 1 year (P = 1.57 x 10(-3) and 2.53 x 10(-2)). CONCLUSION: TTVR is 
      associated with RV remodeling, increased cardiac output, and improvement in NYHA 
      functional class. Using the LuX-Valve for TTVR to treat patients with severe TR 
      is a feasible and relatively safe method with reliable clinical results. Further 
      studies are needed to determine long-term outcomes.
CI  - Copyright (c) 2022 Mao, Li, Liu, Zhai, Ma, Xu, Jin and Yang.
FAU - Mao, Yu
AU  - Mao Y
AD  - Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical 
      University, Xi'an, China.
FAU - Li, Lanlan
AU  - Li L
AD  - Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical 
      University, Xi'an, China.
FAU - Liu, Yang
AU  - Liu Y
AD  - Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical 
      University, Xi'an, China.
FAU - Zhai, Mengen
AU  - Zhai M
AD  - Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical 
      University, Xi'an, China.
FAU - Ma, Yanyan
AU  - Ma Y
AD  - Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical 
      University, Xi'an, China.
FAU - Xu, Chennian
AU  - Xu C
AD  - Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical 
      University, Xi'an, China.
FAU - Jin, Ping
AU  - Jin P
AD  - Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical 
      University, Xi'an, China.
FAU - Yang, Jian
AU  - Yang J
AD  - Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical 
      University, Xi'an, China.
LA  - eng
PT  - Journal Article
DEP - 20221201
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC9751353
OTO - NOTNLM
OT  - LuX-Valve
OT  - follow-up
OT  - transcatheter tricuspid valve replacement
OT  - tricuspid regurgitation
OT  - tricuspid valve
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/20 06:00
MHDA- 2022/12/20 06:01
PMCR- 2022/01/01
CRDT- 2022/12/19 03:58
PHST- 2022/08/15 00:00 [received]
PHST- 2022/11/17 00:00 [accepted]
PHST- 2022/12/19 03:58 [entrez]
PHST- 2022/12/20 06:00 [pubmed]
PHST- 2022/12/20 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fcvm.2022.1019813 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2022 Dec 1;9:1019813. doi: 10.3389/fcvm.2022.1019813. 
      eCollection 2022.